Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Takeda Pharmaceutical Co., Ltd. (OTC: TKPYY).

Full DD Report for TKPYY

You must become a subscriber to view this report.


Recent News from (OTC: TKPYY)

Abivax UC candidate shows positive action in mid-stage study
A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,...
Source: SeekingAlpha
Date: September, 05 2018 12:17
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany
Stocks in News: AZN, AQST AstraZeneca's anifrolumab flunks late-stage lupus study; shares down 1% premarket Discussion: AstraZeneca ( AZN ) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE...
Source: SeekingAlpha
Date: September, 03 2018 10:43
Darzalex combo therapy OK'd in Europe for first-line multiple myeloma
As expected, the European Commission approves Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's DARZALEX (daratumumab), combined with Takeda Pharmaceutical's ( OTCPK:TKPYY ) VELCADE (bortezomib), melphalan and prednisone, for the treatment of adult patients with multiple myeloma in...
Source: SeekingAlpha
Date: August, 31 2018 08:56
Biotech Analysis Central Pharma News: Shire's Results, Novo Nordisk's Goal, Pfizer And Exact Team Up
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Shire Received FDA Approval For Rare Genetic Disease News: Recently, Shire ( SHPG ) announced that it had received FDA approval for its hereditar...
Source: SeekingAlpha
Date: August, 28 2018 12:37
Seattle Genetics Is A Solid Buy In 2018
The year 2018 is definitely turning out to be transformational for Seattle Genetics ( SGEN ). It started with the latest FDA approval for Adcetris, the company’s only marketed product, as front-line therapy in combination with chemotherapy in stage III or IV classical Hodgkin lymphoma o...
Source: SeekingAlpha
Date: August, 27 2018 12:51
23andMe cuts off app developers from raw genetic data
Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te...
Source: SeekingAlpha
Date: August, 24 2018 13:00
Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma
For quite a while now, we've seen a really remarkable transformation in the field of multiple myeloma management. First, we saw the emergence of new crops of targeted therapies with proteasome inhibitors made by outlets like Amgen ( AMGN ) and Takeda ( TKPYY ), as well as Celgene's ( CELG ) su...
Source: SeekingAlpha
Date: August, 24 2018 08:00
Oklahoma first state to negotiate efficacy-based drug prices
Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD...
Source: SeekingAlpha
Date: August, 23 2018 10:54
Your Cancer Highlight: The Study That Could Bridge The New Key Competitors In Kidney Cancer
Of all the forms of cancer that can affect the genitourinary tract, renal cell carcinoma (kidney cancer) has become one of the hotbeds for competition, largely among a boatload of tyrosine kinase inhibitor developers, including Pfizer ( PFE ), Roche ( RHHBF ), Novartis ( NVS ), and Eisai ( ESA...
Source: SeekingAlpha
Date: August, 23 2018 08:00
Merger Arbitrage Mondays: August 13, 2018
Merger activity decreased last week with three new deals announced and one pending deal closing. We also had two deals that failed as discussed in the deal updates section below. After several years of low deal failures (more than 95% of all deals closed), 2018 has turned out to be a difficult...
Source: SeekingAlpha
Date: August, 13 2018 07:53

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1417.4317.1717.7817.127,462,278
2018-12-1317.3017.4417.4617.234,115,220
2018-12-1216.5116.7016.7416.472,007,211
2018-12-1116.3416.2616.4416.106,086,017
2018-12-1016.3916.2816.5216.036,594,208

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-141,247,2416,158,60720.2520Cover
2018-12-131,657,4663,727,24744.4689Short
2018-12-12760,3751,875,61140.5401Short
2018-12-112,124,1745,633,51337.7060Short
2018-12-102,128,7696,490,28832.7993Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TKPYY.


About Takeda Pharmaceutical Co., Ltd. (OTC: TKPYY)

Logo for Takeda Pharmaceutical Co., Ltd. (OTC: TKPYY)

Research amp Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc.

 

Contact Information

 

 

Current Management

  • Yasuchika Hasegawa / President

Current Share Structure

  • Market Cap: $41,994,442,932 - 03/09/2018
  • Issue and Outstanding: 789,666,095 - 06/30/2013

 



Daily Technical Chart for (OTC: TKPYY)

Daily Technical Chart for (OTC: TKPYY)


Stay tuned for daily updates and more on (OTC: TKPYY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TKPYY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TKPYY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TKPYY and does not buy, sell, or trade any shares of TKPYY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/